INO FINAL DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS LAWYERS, Encourages Inovio Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on April 7, 2026 [1] Group 1: Class Action Details - Investors who bought Inovio securities between October 10, 2023, and December 26, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The lawsuit claims that Inovio made false and misleading statements regarding its CELLECTRA device manufacturing and the prospects of its INO-3107 Biologics License Application [5] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience [4] - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]